Fig. 8.

A and B: effect of the IDO inhibitor 1-MT on phenylephrine (PE)-induced (left) and ANG II-induced (right) contraction in without (−)fat and with (+)fat endothelium-intact thoracic aortae (A) and superior mesenteric arteries (B). C, left: direct effect of the IDO metabolite kynurenine on PE-induced (left) contraction in the −fat thoracic aorta. Right, effect of a 1-h incubation of kynurenine (6 mM) on ANG II-induced contraction in the −fat thoracic aorta. D: change in PE-induced contraction in the −fat thoracic aorta caused by basic and acidic vehicles and the downstream IDO metabolites kynuramine, kynurenic acid, xanthurenic acid, and quinolinic acid. Values are means ± SE for the numbers of animals in parentheses. *Significant differences from the appropriate vehicle control (P < 0.05).